Ocular Genomics
243 Charles Street Boston, MA 02114 Contact us
Diagnostic Testing
Support our research
Explore our labs
Ocular Genomics MENU
Ocular Genomics
  • News & Publications
    • RETINAL Transcriptome
  • Affiliates
  • Careers
  • Rates
  • Order Information
  • Contact Us
  • Pricing
  • Home
  • 2017
  • September

Featured Posts

  • Work by Caitlin Collin & Qin Liu highlighted at ARVO 2021 meeting
  • Ground-breaking study to restore vision uses CRISPR technology
  • Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder

Recent Posts

  • Precision Medicine at Work
  • Work by Caitlin Collin & Qin Liu highlighted at ARVO 2021 meeting
  • Ground-breaking study to restore vision uses CRISPR technology
  • Ocular Genomics Institute Scientists publish large Gene-Wide Association Study of Glaucoma
  • AAVCOVID Vaccine developed by Luk Vandenberghe to start Clinical trials

Archives

  • June 2021
  • May 2021
  • March 2021
  • February 2021
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • June 2020
  • August 2019
  • May 2019
  • April 2019
  • May 2018
  • April 2018
  • March 2018
  • November 2017
  • September 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017

Categories

  • News
  • Publication
  • Uncategorized
Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type 10 (LCA10)
September 21, 2017

Massachusetts Eye and Ear named as first site for the study   CAMBRIDGE, Mass., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that the Company initiated a clinical natural history study of Leber Congenital Amaurosis type 10 (LCA10). LCA10 is caused by mutations... Read More


Featured:

Contact Us

243 Charles Street
Boston, MA 02114

Labs

Sitemap

  • Affiliates
  • Careers
  • News & publications
  • Support Our Research
  • Privacy
website-boston WebsiteBoston